On April 20, 2026 NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, reported the presentation of new preclinical data evaluating its Nanoprimer platform in sequence with lipid nanoparticle-delivered recombinant DNA ("LNP-DNA") at the 2026 Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
POSTER #6389: Maximizing systemic LNP-DNA delivery for cancer-activated expression of Immunotherapy agents using Nanoprimer technology
Background
A key limitation common to LNP-DNA is rapid hepatic clearance via the mononuclear phagocyte system ("MPS"), which can reduce systemic bioavailability and tumor accumulation, as well as increase hepatic toxicity. In addition, LNP-DNA may trigger transient acute inflammation through activation of the cGAS/STING pathway.
In this evaluation, LNP-DNA vehicles designed for anti-tumor immunotherapy were administered with or without Nanobiotix Nanoprimer pre-treatment in a mouse model. Nanoprimer is designed to transiently occupy hepatic clearance pathways such as MPS to increase bioavailability and target accumulation, while reducing hepatic toxicity. Both agents were administered intravenously (IV).
Key Observations
Reduced hepatic exposure and toxicity:
Decreased liver uptake of LNP-DNA and improved hepatic tolerability
Improved systemic bioavailability:
Increase in circulating levels of LNP-DNA
Mitigation of inflammatory response:
Attenuated activation of cGAS-STING pathway downstream targets
Potentially broad applicability across LNP designs:
Notably, these LNP-DNA formulations were specifically engineered for extrahepatic delivery, supporting the potential of the Nanoprimer to further optimize advanced delivery systems
Conclusions
These data support further evaluation of Nanoprimer in sequence with innovative LNP-delivered therapies
Advanced LNP systems designed for extrahepatic delivery could potentially be further optimized to improve systemic bioavailability and reduce toxicity through sequencing with the Nanoprimer
"We continue our dual path approach to the development of our next-wave Nanoprimer platform in which we are both pursuing external collaborations with partners developing innovative therapeutic candidates that are challenged by liver accumulation, as well as our own proprietary internal pipeline," said Laurent Levy Nanobiotix Chief Executive Officer and Chairman of the Executive Board. "We are encouraged by these preclinical results, generated in collaboration with Earli, which further support our hypothesis that the Nanoprimer may improve therapeutic efficacy while mitigating toxicity when sequenced prior to the administration of advanced therapeutics such as LNP-DNA and an additional layer of proof of concept."
About NANOPRIMER
The Nanoprimer is an early-stage nanotherapeutic platform designed to disrupt the design and development of innovative therapeutics and improve outcomes for patients. The Nanoprimer potentially increases drug bioavailability or decreases unintended off-target effects in the liver, specifically hepatic toxicity. The platform is designed for use in combination with advanced therapeutics across multiple drug classes. The Nanoprimer is being developed through external collaborations and an internal proprietary pipeline.
Nanoprimer is an early-stage nanotherapeutic platform designed to unleash the potential of advanced therapeutics by addressing one of the most common structural limitations in modern medicine: liver uptake and extrahepatic delivery. As therapies become more complex—such as RNA, gene therapies, and advanced biologics—they are increasingly captured by the liver, limiting their ability to reach target tissues and reducing their effectiveness.
Nanoprimer transiently modulates this natural clearance, allowing more drug to circulate longer, reach its intended target, and reduce off-target liver exposure.This approach can both enhance the performance of existing therapies and unlock new therapeutic pathways that were previously not achievable.
Developed as a therapeutic companion platform, Nanobiotix is advancing this technology through strategic external collaborations alongside a proprietary internal pipeline of Nanoprimer-enabled assets.
(Press release, Nanobiotix, APR 20, 2026, View Source [SID1234664544])